633 related articles for article (PubMed ID: 26206510)
1. Novel Small Molecule Entry Inhibitors of Ebola Virus.
Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection.
Côté M; Misasi J; Ren T; Bruchez A; Lee K; Filone CM; Hensley L; Li Q; Ory D; Chandran K; Cunningham J
Nature; 2011 Aug; 477(7364):344-8. PubMed ID: 21866101
[TBL] [Abstract][Full Text] [Related]
3. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.
Shoemaker CJ; Schornberg KL; Delos SE; Scully C; Pajouhesh H; Olinger GG; Johansen LM; White JM
PLoS One; 2013; 8(2):e56265. PubMed ID: 23441171
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
5. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
Morales-Tenorio M; Ginex T; Cuesta-Geijo MÁ; Campillo NE; Muñoz-Fontela C; Alonso C; Delgado R; Gil C
Eur J Med Chem; 2021 Nov; 223():113654. PubMed ID: 34175537
[TBL] [Abstract][Full Text] [Related]
6. Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by
Mittler E; Alkutkar T; Jangra RK; Chandran K
mBio; 2021 Jan; 12(1):. PubMed ID: 33436438
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.
Zhang X; Ao Z; Bello A; Ran X; Liu S; Wigle J; Kobinger G; Yao X
Antiviral Res; 2016 Mar; 127():20-31. PubMed ID: 26778707
[TBL] [Abstract][Full Text] [Related]
8. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
[TBL] [Abstract][Full Text] [Related]
9. Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry.
Bo Y; Qiu S; Mulloy RP; Côté M
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493822
[TBL] [Abstract][Full Text] [Related]
10. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway.
Spence JS; Krause TB; Mittler E; Jangra RK; Chandran K
mBio; 2016 Feb; 7(1):e01857-15. PubMed ID: 26861015
[TBL] [Abstract][Full Text] [Related]
11. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry.
Schafer A; Xiong R; Cooper L; Nowar R; Lee H; Li Y; Ramirez BE; Peet NP; Caffrey M; Thatcher GRJ; Saphire EO; Cheng H; Rong L
PLoS Pathog; 2021 Feb; 17(2):e1009312. PubMed ID: 33539432
[TBL] [Abstract][Full Text] [Related]
12. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
Beck S; Henß L; Weidner T; Herrmann J; Müller R; Chao YK; Grimm C; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Aug; 132():85-91. PubMed ID: 27241689
[TBL] [Abstract][Full Text] [Related]
13. Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein.
Li Q; Ma L; Yi D; Wang H; Wang J; Zhang Y; Guo Y; Li X; Zhou J; Shi Y; Gao GF; Cen S
Antiviral Res; 2018 Jul; 155():1-11. PubMed ID: 29709562
[TBL] [Abstract][Full Text] [Related]
14. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step.
Mingo RM; Simmons JA; Shoemaker CJ; Nelson EA; Schornberg KL; D'Souza RS; Casanova JE; White JM
J Virol; 2015 Mar; 89(5):2931-43. PubMed ID: 25552710
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976.
Hofmann-Winkler H; Gnirß K; Wrensch F; Pöhlmann S
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S172-80. PubMed ID: 25840443
[TBL] [Abstract][Full Text] [Related]
16. Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments.
Stewart CM; Phan A; Bo Y; LeBlond ND; Smith TKT; Laroche G; Giguère PM; Fullerton MD; Pelchat M; Kobasa D; Côté M
PLoS Pathog; 2021 Jan; 17(1):e1009275. PubMed ID: 33513206
[TBL] [Abstract][Full Text] [Related]
17. Synergistic drug combination effectively blocks Ebola virus infection.
Sun W; He S; Martínez-Romero C; Kouznetsova J; Tawa G; Xu M; Shinn P; Fisher E; Long Y; Motabar O; Yang S; Sanderson PE; Williamson PR; García-Sastre A; Qiu X; Zheng W
Antiviral Res; 2017 Jan; 137():165-172. PubMed ID: 27890675
[TBL] [Abstract][Full Text] [Related]
18. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses.
Lasala F; García-Rubia A; Requena C; Galindo I; Cuesta-Geijo MA; García-Dorival I; Bueno P; Labiod N; Luczkowiak J; Martinez A; Campillo NE; Alonso C; Delgado R; Gil C
Antiviral Res; 2021 Feb; 186():105011. PubMed ID: 33428961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
